AbbVie’s board is telling shareholders to vote against its own $55 billion takeover bid for the Irish drugmaker Shire after the U.S. made reincorporating overseas a less lucrative tax maneuver.

The company, based in North Chicago, Illinois, said late Wednesday that changes led by the U.S. Treasury Department introduced an “unacceptable level of uncertainty” and eliminated some of the financial benefits.

Recommended Stories

Congress takes aim again at pharmaceutical giant over patent-stacking for brand-name drugs

Burger King makes move to Canada official

House Democrats open wide-reaching investigation into Big Pharma